Production (Stage)
Navco Pharmaceuticals Inc.
NAV.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 96.25% | -164.56% | 94.79% | -819.06% | -184.76% |
| Total Depreciation and Amortization | -93.83% | -93.90% | 210.98% | 146.91% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.69% | 139.38% | -99.93% | 3,204.00% | -48.00% |
| Change in Net Operating Assets | -93.96% | 187.59% | 114.13% | 1,333.96% | -14.45% |
| Cash from Operations | 99.36% | 94.38% | 98.17% | -265.74% | -411.68% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 19.35% | 27.54% | 88.51% | -133.33% | 80.38% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 20.00% | 163.89% | -97.19% | -100.31% | 80.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.23% | 99.23% | 98.78% | -103.80% | -1,066.10% |